Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine

Amir Sarayani, Brian Cicali, Carl H Henriksen, Joshua D Brown

Research in Social and Administrative Pharmacy, vol. 17, Elsevier, 2021, pp. 483--486

Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic.

Joshua D Brown

Research in social \& administrative pharmacy: RSAP, 2020

Antihypertensive drugs and risk of COVID-19?

Joshua D Brown

The Lancet. Respiratory Medicine, vol. 8, Elsevier, 2020, pp. e28

Potential adverse drug events and drug--drug interactions with medical and consumer cannabidiol (CBD) use

Joshua D Brown, Almut G Winterstein

Journal of clinical medicine, vol. 8, Multidisciplinary Digital Publishing Institute, 2019, p. 989

Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis

Ghadeer K Dawwas, Joshua Brown, Eric Dietrich, Haesuk Park

The Lancet Haematology, vol. 6, Elsevier, 2019, pp. e20--e28